Drugs / PRT3645
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05538572 | Dec 2022 → Jun 2024 | breast cancer, endometrial cancer, glioblastoma, head and neck squamous cell carcinoma +3 | Prelude Therapeutics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2024-04-09 | Prelude Therapeutics | Results Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting preludetx.com ↗
Potentially best-in-class CDK9 inhibitor, PRT2527, in Phase 1 development, is highly effective in preclinical hematological models as monotherapy and provides improved depth and duration of response in combination with BTK/BCL2 inhibition |
| 2023-10-14 | Prelude Therapeutics | Results Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference preludetx.com ↗
We also presented our initial clinical data with our differentiated brain and tissue penetrant next generation CDK4/6 inhibitor, PRT3645, demonstrating a generally well-tolerated safety profile and high target inhibition reaching levels needed for efficacy in preclinical studies. |
| 2022-11-14 | Prelude Therapeutics | Regulatory Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update preludetx.com ↗
We made meaningful advancements in the third quarter and to date in the fourth quarter, including FDA clearance for two new INDs, one for PRT3645, a next generation, brain penetrant CDK4/6 inhibitor and one for PRT3789, a novel, first-in-class selective SMARCA2 degrader. |
| 2022-08-09 | Prelude Therapeutics | Regulatory Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update preludetx.com ↗
Today, Prelude is pleased to announce the acceptance of our latest IND for PRT3645, a differentiated and highly brain penetrant CDK4/6 inhibitor. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-04-09 | Prelude Therapeutics | Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting preludetx.com ↗ |
| 2023-10-14 | Prelude Therapeutics | Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference preludetx.com ↗ |
| 2022-11-14 | Prelude Therapeutics | Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update preludetx.com ↗ |
| 2022-08-09 | Prelude Therapeutics | Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update preludetx.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRT3645 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05538572 ↗ |
| Action | Inhibit | “CDK4/6 inhibitor” NCT05538572 ↗ |
| Target | CDK4 | “CDK4/6 inhibitor” NCT05538572 ↗ |